Dimerix (ASX:DXB) has reached a significant milestone in its late-stage clinical program, announcing that its global ACTION3 Phase 3 trial of DMX-200 for focal segmental glomerulosclerosis has now completed recruitment and dosing of its target 286 adult patients. …
Dimerix completes adult recruitment in Phase 3 trial for FSGS treatment DMX-200
December 15, 2025 Australian Biotech
Latest Video
New Stories
-
The industry walked out on Britain, and what it cost to win them back
October 22, 2026 - - Latest News -
BioNTech opens mRNA plant, putting Melbourne's north on the biotech map
October 22, 2026 - - Latest News -
An architect of the first industry–Commonwealth medicines pact to lead CSL
October 21, 2026 - - Latest News -
Quarterly update shows Telix holds course for a US$1 billion milestone year
October 21, 2026 - - Latest News -
Chemist Warehouse keeps growing as Sigma sets its sights on oral GLP-1s
October 21, 2026 - - Latest News -
America's ever rising GLP-1 curve and how Australia is following
October 21, 2026 - - Latest News -
Patient groups across Asia-Pacific push for a say on medicine prices
October 21, 2026 - - Latest News